Healthcare Industry News: Artificial Heart
News Release - June 24, 2009
Abiomed Announces First FDA-Approved AbioCor(R) Implant at UMDNJ-Robert Wood Johnson Medical School and Robert Wood Johnson University HospitalEnd-Stage Heart Failure Patient Receives AbioCor; Recovering Well Post-Surgery
DANVERS, Mass.--(HSMN NewsFeed)--Abiomed, Inc. (NASDAQ: ABMD ), today announced the successful implant of its AbioCor(R) Total Replacement Heart, performed at Robert Wood Johnson University Hospital by Mark Anderson, M.D., associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School and chief of the section of cardiac surgery at both the medical school and Robert Wood Johnson University Hospital. This is the first AbioCor implant since the completion of clinical trials and Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration (FDA) on September 5, 2006.
The 76-year-old male patient was diagnosed with congestive, end-stage heart failure and did not qualify for a heart transplant or other available therapies, making him eligible for the AbioCor implant. More than one week after the surgery, the patient is showing signs of a strong and stable recovery.
“We are honored to be among the few distinguished institutions in the nation to offer this innovative technology to patients who have no other treatment alternatives available to them,” said Dr. Anderson. “The implantation marks the culmination of nearly three decades of research and development and the technology has finally reached the point where an Artificial Heart has become a real option for end-stage heart failure patients. We believe this procedure is a significant step toward offering new hope and a future to patients who may still have more quality time with their family and loved ones.”
“The AbioCor is designed to give end stage heart failure patients another treatment option to extend their quality of life when they are ineligible for all other medical therapies,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “We are thrilled to be working with the renowned Robert Wood Johnson University Hospital.”
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
Abiomed, Impella, iPulse, BVS5000, AB5000, AbioCor and the Abiomed logo are all trademarks of Abiomed. Other company and product names may be trademarks of their respective owners.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.